APA (7th ed.) Citation

MB, G., T, M., J, T., E, C., H, H., D, B., . . . JPT, C. (2023). Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. British journal of clinical pharmacology, 89(12), 3573. https://doi.org/10.1111/bcp.15854

Chicago Style (17th ed.) Citation

MB, Goncalves, et al. "Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Results of KCL-286, a Novel Retinoic Acid Receptor-β Agonist for Treatment of Spinal Cord Injury, in Male Healthy Participants." British Journal of Clinical Pharmacology 89, no. 12 (2023): 3573. https://doi.org/10.1111/bcp.15854.

MLA (9th ed.) Citation

MB, Goncalves, et al. "Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Results of KCL-286, a Novel Retinoic Acid Receptor-β Agonist for Treatment of Spinal Cord Injury, in Male Healthy Participants." British Journal of Clinical Pharmacology, vol. 89, no. 12, 2023, p. 3573, https://doi.org/10.1111/bcp.15854.